KAREN RABIN to Down Syndrome
This is a "connection" page, showing publications KAREN RABIN has written about Down Syndrome.
Connection Strength
6.883
-
Outcomes in Children, Adolescents, and Young Adults With Down Syndrome and ALL: A Report From the Children's Oncology Group. J Clin Oncol. 2024 Jan 10; 42(2):218-227.
Score: 0.739
-
Management of Down Syndrome-Associated Leukemias: A Review. JAMA Oncol. 2023 09 01; 9(9):1283-1290.
Score: 0.731
-
Patients with Down syndrome can be included in early phase clinical trials- a report from the T2016-003 Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) study. Leukemia. 2023 05; 37(5):1138-1140.
Score: 0.705
-
Risk stratification for Down syndrome and acute lymphocytic leukaemia: one size does not fit all. Lancet Haematol. 2021 Oct; 8(10):e673-e675.
Score: 0.640
-
Need for new thinking: Treatment of relapsed leukemia in children with Down syndrome. Pediatr Blood Cancer. 2019 06; 66(6):e27644.
Score: 0.533
-
Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer. 2012 Apr; 58(4):633-5.
Score: 0.323
-
Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 2011 Oct; 25(10):1555-63.
Score: 0.313
-
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat Genet. 2009 Nov; 41(11):1243-6.
Score: 0.279
-
Malignancy in children with trisomy 21. Oncologist. 2009 Feb; 14(2):164-73.
Score: 0.266
-
Prevalence and clinical correlates of JAK2 mutations in Down syndrome acute lymphoblastic leukaemia. Br J Haematol. 2009 Mar; 144(6):930-2.
Score: 0.264
-
Differential in vitro cytotoxicity does not explain increased host toxicities from chemotherapy in Down syndrome acute lymphoblastic leukemia. Leuk Res. 2009 Feb; 33(2):336-9.
Score: 0.258
-
Imagine, Discover, Inspire: Proceedings of the 4th International Conference of the Trisomy 21 Research Society. Neuromolecular Med. 2025 Jan 05; 27(1):5.
Score: 0.201
-
Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome. Blood Adv. 2023 11 14; 7(21):6532-6539.
Score: 0.185
-
Down syndrome and leukemia: from basic mechanisms to clinical advances. Haematologica. 2023 10 01; 108(10):2570-2581.
Score: 0.184
-
Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023 07 13; 142(2):172-184.
Score: 0.181
-
Epigenome-wide association study of acute lymphoblastic leukemia in children with Down syndrome. Blood Adv. 2022 07 26; 6(14):4132-4136.
Score: 0.169
-
CRLF2 overexpression results in reduced B-cell differentiation and upregulated E2F signaling in the Dp16 mouse model of Down syndrome. Exp Hematol. 2022 06; 110:34-38.
Score: 0.165
-
Enhancer polymorphisms at the IKZF1 susceptibility locus for acute lymphoblastic leukemia impact B-cell proliferation and differentiation in both Down syndrome and non-Down syndrome genetic backgrounds. PLoS One. 2021; 16(1):e0244863.
Score: 0.152
-
The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS One. 2020; 15(9):e0239040.
Score: 0.149
-
Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome. Blood. 2019 10 10; 134(15):1227-1237.
Score: 0.140
-
Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group. Blood Adv. 2019 06 11; 3(11):1647-1656.
Score: 0.136
-
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group. Blood. 2014 Jan 02; 123(1):70-7.
Score: 0.093
-
Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
Score: 0.078